Mobidiag and Unilabs Enter into Agreement
News Sep 01, 2015
Mobidiag Ltd and Unilabs have announced an agreement covering the supply of Amplidiag products over the next four years for Unilabs in Sweden and Norway.
The Amplidiag product line covers six diagnostic products for various gastrointestinal infections, including tests for gastroenteritis, carbapenem- and vancomycin-resistance screening, as well as non-invasive Helicobacter pylori testing. The product line brings a major improvement to clinical laboratory processes, patient management and infection control measures by providing sensitive, comprehensive and rapid diagnostic results.
“Molecular diagnostics is gaining traction and becoming an increasingly important tool in improving patient diagnostics”, says Helena Enroth, PhD, responsible for R&D in molecular microbiology, Unilabs Sweden. “Implementing new multiplex molecular diagnostic tools is a step forward in our efforts to continuously improve our service portfolio and meet customer demands. Mobidiag is able to offer a comprehensive suite for gastrointestinal testing, and importantly, the products meet our expectations for large-scale use.”
“We are very happy to enter into this agreement”, says Tuomas Tenkanen, CEO of Mobidiag. “It is a major step forward in our efforts to enter the European market, and a major step in bringing Amplidiag products into the high-throughput use they have been designed for. This agreement solidifies our belief that we are able to create value together with our customers by bringing affordable molecular multiplex tests into clinical laboratory routines. We are very pleased to work together with Unilabs.”
Tweak to Technique Could Bolster Disease DetectionNews
A team of Stanford researchers has developed a technique that they hope could more precisely detect diseases or disorders such as cancer or a heart attack.READ MORE
Immune Cells That Keep Gut Fungi Under Control IdentifiedNews
Immune cells that process food and bacterial antigens in the intestines control the intestinal population of fungi, according to a new study from Weill Cornell Medicine scientists.READ MORE
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018